- GlobeNewswire•16 days agoCascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast Cancer
SEATTLE, Oct. 10, 2016-- Cascadian Therapeutics, a clinical-stage biopharmaceutical company, today announced the presentation of clinical activity of tucatinib, its investigational, highly selective small ...
- Zacks•19 days ago
As of late, it has definitely been a great time to be an investor in Cascadian Therapeutics Inc (CASC).
- GlobeNewswire•21 days ago
SEATTLE, Oct. 04, 2016-- Cascadian Therapeutics, a clinical-stage biopharmaceutical company, today announced that its board of directors has approved a plan for a reverse split of the Company’ s common ...
Cascadian Therapeutics, Inc. (CASC)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||1.10 x 1000|
|Ask||2.20 x 200|
|Day's Range||1.20 - 1.24|
|52wk Range||0.82 - 1.83|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.25|
|Avg Vol (3m)||585,041|
|Dividend & Yield||0.00 (0.00%)|